Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

Yeon, J. E.; Yoo, W.; Hong, S. P.; Chang, Y. J.; Yu, S. K.; Kim, J. H.; Seo, Y. S.; Chung, H. J.; Moon, M. S.; Kim, S.-O.; Byun, K. S.; Lee, C. H.
October 2006
Gut;Oct2006, Vol. 55 Issue 10, p1488
Academic Journal
Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8–3%, and ∼5.9%, respectively. Aims: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. Methods: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). Results: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12–17, 3–19, and 7–20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. Conclusion: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naïve patients.


Related Articles

  • HBeAg NEGATIVE CHRONIC HEPATITIS B: AN OVERVIEW. Akbar, S. M. Fazle // Hepatitis B Annual;2009, Vol. 6, p131 

    Over 350 million people worldwide are infected with hepatitis B virus (HBV), and patients with HBeAg-negative chronic hepatitis B constitute a major proportion of this population. Mutant varieties of HBV resulting from mutations in the precore or core promoter region of the viral genome give...

  • Are Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B and HBeAg-Negative Chronic Hepatitis B Distinct Diseases? Nguyen, Mindie H.; Keeffe, Emmet B. // Clinical Infectious Diseases;11/15/2008, Vol. 47 Issue 10, p1312 

    The article offers information on the relationship of Hepatitis B e Antigen (HBeAg), positive chronic Hepatitis B and HBeAg-negative Chronic Hepatitis B. It outlines the factors for the current treatment of chronic Hepatitis B as well as the significance of the guidelines and recommended...

  • Virologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHB.  // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p262 

    The article focuses on a study which analyzes the virologic and clinical features of genotypes related to hepatitis B virus (HBV) in children with chronic hepatitis B (CHB) virus infection in China. In the study 487 Chinese pediatric patients with CHB were included and direct sequencing was used...

  • Evolution of HBeAg/Anti--HBe Status and Its Relationship to Clinical and Histological Outcome in Chronic HBV Carriers in Childhood. Sodeyama, Takeshi; Kiyosawa, Kendo; Akahane, Yoshihiro; Tanaka, Eiji; Wada, Shuichi; Oike, Yoshimoto; Nakamura, Makoto; Yoda, Hidetoshi; Imai, Yasuharu; Gibo, Yukio; Nagata, Atsuo; Furuta, Seiichi // American Journal of Gastroenterology;Apr1986, Vol. 81 Issue 4, p239 

    Fifty-five Japanese HBV carriers under 15 yr of age were followed for 12 months or longer, during which time we investigated the evolution of HBeAg/anti-HBe status and clinical and histological aspects of the liver disease. Of 45 cases positive for HBeAg at the initial examination, 34 remained...

  • Predictive value of HBcrAg for lamivudine resistance in patients with chronic hepatitis B. LIU Cheng; MU Yongping; YANG Zongguo // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;nov2013, Vol. 29 Issue 11, p820 

    Objective To evaluate the predictive value of hepatitis B virus (HBV) core - related antigen (HBcrAg) for the lamivudine (LAM) resistance in patients with chronic hepatitis B. Methods Forty - three patients with previously untreated chronic hepatitis B who were treated in the inpatient...

  • Development of Cirrhosis after Chronic Type B Hepatitis: A Clinicopathologic and Follow--up Study of 46 HBeAg--Positive Asymptomatic Patients. Moreno-Otero, Ricardo; García-Monzón, Carmelo; García-Sánchez, Asunción; Buey, Luisa García; Pajares, José M.; Di Bisceglie, Adrian M. // American Journal of Gastroenterology;May1991, Vol. 86 Issue 5, p560 

    The rate of HBeAg clearance and the outcome were analyzed in 46 patients with asymptomatic chronic hepatitis B virus (HBV) infection whose condition was followed for 1-4 yr (mean 2.4). Mean age was 32.5 yr (range 10-68), and 28 (61%) were males. All had chronic hepatitis, on biopsy, and were...

  • Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2. Trottier, Benoit; Di Perri, Giovanni; Madruga, José Valdez; Peeters, Monika; Vingerhoets, Johan; Picchio, Gaston; Woodfall, Brian J. // HIV Clinical Trials (Thomas Land Publishers Incorporated);Jul/Aug2010, Vol. 11 Issue 4, p175 

    Purpose: This subgroup analysis of the phase 3 DUET trials examined the impact of the background regimen on virologic response to etravirine in treatment-experienced patients. Methods: Patients received etravirine 200 mg or placebo, both twice daily with a background regimen of...

  • HEPATITIS B. Kassianos, George // Pulse;12/10/2005, Vol. 65 Issue 48, p43 

    The article presents the author's view on Hepatitis B. George Kassianos shares his insights gained from working as a general practitioner. He informed that tattoos and piercing, plus sharing of personal items such as tooth brushes, razors and earrings can all lead to exposure to infected blood...

  • HEPATITIS B AND RENAL TRANSPLANTATION: DANGLING THE SWORD OF DAMOCLES? Ryan, Michael J.; Johnson, David A.; Cattau Jr., Edward L. // American Journal of Gastroenterology;Dec1992, Vol. 87 Issue 12, p1882 

    Comments on a study on the increased risk of fatal liver disease in renal transplant patients who are hepatitis B antigen and/or hepatitis B virus DNA positive by Fairley C. R. et al, published in a 1991 issue of "Transplantation." Abstract of the study; Key findings; Criticisms.


Read the Article


Sign out of this library

Other Topics